0000950170-24-073769.txt : 20240614 0000950170-24-073769.hdr.sgml : 20240614 20240614170011 ACCESSION NUMBER: 0000950170-24-073769 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240611 ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lineage Cell Therapeutics, Inc. CENTRAL INDEX KEY: 0000876343 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943127919 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12830 FILM NUMBER: 241045729 BUSINESS ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 BUSINESS PHONE: 5105213390 MAIL ADDRESS: STREET 1: 2173 SALK AVENUE STREET 2: SUITE 200 CITY: CARLSBAD STATE: CA ZIP: 92008 FORMER COMPANY: FORMER CONFORMED NAME: BIOTIME INC DATE OF NAME CHANGE: 19930328 8-K 1 lctx-20240614.htm 8-K 8-K
0000876343false00008763432024-06-142024-06-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2024

 

 

Lineage Cell Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

California

001-12830

94-3127919

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2173 Salk Avenue, Suite 200

 

Carlsbad, California

 

92008

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (442) 287-8990

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common shares

 

LCTX

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 4.01 Changes in Registrant’s Certifying Accountant.

(a) Previous Independent Registered Public Accounting Firm

 

On June 11, 2024, the Audit Committee of the Board of Directors of Lineage Cell Therapeutics, Inc. (the “Company”) approved the dismissal of WithumSmith+Brown, PC (“Withum”), as the Company’s independent registered public accounting firm, effective on that date. Withum audited the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022. Withum’s report dated March 7, 2024, with respect to the consolidated financial statements of the Company as of December 31, 2023 and 2022 and for each of the years ended December 31, 2023 and 2022, did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles. During the two years ended December 31, 2023, and from December 31, 2023 through June 11, 2024, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between the Company and Withum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Withum, would have caused Withum to make reference to the subject matter of such disagreements in connection with its report, or (ii) “reportable events,” as described in Item 304(a)(1)(v) of Regulation S-K, that would require disclosure under Item 304(a)(1)(v) of Regulation S-K.

The Company furnished Withum with a copy of the disclosure in this Item 4.01 and requested that Withum furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission stating whether Withum agrees with the statements made by the Company in this Item 4.01, and if not, stating the respects in which it does not agree. Withum furnished such a letter, a copy of which is filed as Exhibit 16.1 to this report.

(b) New Independent Registered Public Accounting Firm

 

Also on June 11, 2024, and effective as of that date, the Audit Committee of the Board of Directors of the Company approved the engagement of Moss Adams LLP (“Moss Adams”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. During the Company’s two most recent fiscal years and the subsequent interim period through June 11, 2024, neither the Company, nor any person acting on its behalf, consulted Moss Adams regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of the audit opinion that might be rendered on the Company’s financial statements, and Moss Adams did not provide any written report or oral advice to the Company that Moss Adams concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

 

Description

16.1

 

Letter from WithumSmith+Brown, PC dated June 11, 2024

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Lineage Cell Therapeutics, Inc.

 

 

 

 

Date:

June 14, 2024

By:

/s/ George A. Samuel III

 

 

Name:

Title:

George A. Samuel III
General Counsel and Corporate Secretary

 

 EX-16.1 2 lctx-ex16_1.htm EX-16.1 EX-16.1

EXHIBIT 16.1

June 11, 2024

Office of the Chief Accountant

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen:

We have read the statements included under Item 4.01 of the Form 8-K dated June 11, 2024 to be filed by our former client Lineage Cell Therapeutics, Inc. We agree with the statements under Item 4.01 insofar as they relate to our Firm. We are not in a position to agree or disagree with other statements contained therein.

Very truly yours,

/s/WithumSmith+Brown, PC

San Francisco, California

 EX-101.SCH 3 lctx-20240614.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 5 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document And Entity Information
Jun. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2024
Entity Registrant Name Lineage Cell Therapeutics, Inc.
Entity Central Index Key 0000876343
Entity Emerging Growth Company false
Entity File Number 001-12830
Entity Incorporation, State or Country Code CA
Entity Tax Identification Number 94-3127919
Entity Address, Address Line One 2173 Salk Avenue, Suite 200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92008
City Area Code (442)
Local Phone Number 287-8990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares
Trading Symbol LCTX
Security Exchange Name NYSEAMER
EXCEL 6 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 7 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports [dq-0540-DocumentPeriodEndDate-Value] In submission type 8-K, DocumentPeriodEndDate value 2024-06-11, is not equivalent to header element periodOfReport value, 06-14-2024, in the Required Context. lctx-20240614.htm 22 [dqc-0036-Document-Period-End-Date-Context-Fact-Value-Check] The ending date of 2024-06-14 used for DocumentPeriodEndDate must be the same as the Document Period End Date, 2024-06-11. The properties of this DocumentPeriodEndDate fact are Context: C_45e7d749-bc48-4863-91d0-f2a0a0ab99db, Rule Element Id: 1. lctx-20240614.htm 22 lctx-20240614.htm lctx-20240614.xsd http://xbrl.sec.gov/dei/2024 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "lctx-20240614.htm": { "nsprefix": "lctx", "nsuri": "http://lineagecell.com/20240614", "dts": { "inline": { "local": [ "lctx-20240614.htm" ] }, "schema": { "local": [ "lctx-20240614.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_45e7d749-bc48-4863-91d0-f2a0a0ab99db", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lctx-20240614.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_45e7d749-bc48-4863-91d0-f2a0a0ab99db", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "lctx-20240614.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://lineagecell.com/20240614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0000950170-24-073769-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-073769-xbrl.zip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end XML 16 lctx-20240614_htm.xml IDEA: XBRL DOCUMENT 0000876343 2024-06-14 2024-06-14 0000876343 false 8-K 2024-06-11 Lineage Cell Therapeutics, Inc. CA 001-12830 94-3127919 2173 Salk Avenue, Suite 200 Carlsbad CA 92008 (442) 287-8990 false false false false Common shares LCTX NYSEAMER false